Results 51 to 60 of about 2,437,393 (325)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Antibody and B cell responses to Plasmodium sporozoites [PDF]

open access: yes, 2014
Antibodies are capable of blocking infection of the liver by Plasmodium sporozoites. Accordingly the induction of anti-sporozoite antibodies is a major aim of various vaccine approaches to malaria.
Cockburn, Ian A.   +2 more
core   +2 more sources

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin   +2 more
wiley   +1 more source

Timing of Assessment of Humoral and Cell-Mediated Immunity after Influenza Vaccination

open access: yesVaccines
Assessment of the immune response to influenza vaccines should include an assessment of both humoral and cell-mediated immunity. However, there is a lack of consensus regarding the timing of immunological assessment of humoral and cell-mediated immunity ...
Naruhito Otani   +11 more
doaj   +1 more source

Clinical and Immunological Efficacy of Treating Children with Bronchial Obstruction Associated with Atypical Pathogens

open access: yesZdorovʹe Rebenka, 2015
This article provides information about the clinical course of bronchial obstruction caused by intracellular infection, and the impact of intracellular infection on the cellular, humoral and local immunity in children.
M.P. Prokhorova
doaj   +1 more source

Retrospective of International Serological Studies on the Formation and Dynamics of the Humoral Immune Response to SARS-CoV-2: from 2020 to 2021

open access: yesActa Biomedica Scientifica, 2021
Last year the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has started. The new coronavirus is highly contagious and causes severe complications.
E. A. Novikova   +4 more
doaj   +1 more source

Rectal Microbiome Composition Correlates with Humoral Immunity to HIV-1 in Vaccinated Rhesus Macaques. [PDF]

open access: yes, 2019
The microbiome is an integral and dynamic component of the host and is emerging as a critical determinant of immune responses; however, its influence on vaccine immunogenicity is largely not well understood.
Dinasarapu, Ashok R   +9 more
core   +1 more source

Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity.

open access: yesNano letters (Print), 2019
Lymph node follicles capture and retain antigens to induce germinal centers and long-lived humoral immunity. However, control of antigen retention has been limited.
Yi-Nan Zhang   +6 more
semanticscholar   +1 more source

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

open access: yesNew England Journal of Medicine, 2021
Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel.
Einav G. Levin   +13 more
semanticscholar   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy